Mark K. White - 17 Nov 2023 Form 4 Insider Report for Annovis Bio, Inc. (ANVS)

Role
Director
Signature
/s/ Maria Maccecchini Attorney-in-Fact
Issuer symbol
ANVS
Transactions as of
17 Nov 2023
Net transactions value
$0
Form type
4
Filing time
03 Jul 2024, 17:18:10 UTC
Previous filing
11 Apr 2023
Next filing
22 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANVS Stock Option (right to buy) Award $0 +26,200 $0.000000 26,200 17 Nov 2023 Common Stock 26,200 $6.07 Direct F1, F2
transaction ANVS Stock Option (right to buy) Award $0 +2,146 $0.000000 2,146 27 Nov 2023 Common Stock 2,146 $7.39 Direct F2, F3
transaction ANVS Stock Option (right to buy) Award $0 +20,000 $0.000000 20,000 01 Jul 2024 Common Stock 20,000 $5.27 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 12, 2024, stockholders of Annovis Bio, Inc. ("the Company") approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved.
F2 The stock option shall vest immediately upon grant date.
F3 The stock option was granted in consideration for consulting services that reporting person will perform for the Company.
F4 The stock option shall vest in quarterly increments, based upon the services performed by the reporting person under the related Consulting Agreement.